
Jung-Woo Chae

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/491322/publications.pdf Version: 2024-02-01



LUNC-MOO CHAF

#	Article	IF	CITATIONS
1	Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel. Carbohydrate Polymers, 2021, 253, 117187.	10.2	41
2	Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. PLoS ONE, 2016, 11, e0164204.	2.5	36
3	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. Journal of Pain and Symptom Management, 2018, 55, 992-997.e2.	1.2	31
4	Pharmacokinetic characterization of decursinol derived from <i>Angelica gigas</i> Nakai in rats. Xenobiotica, 2011, 41, 895-902.	1.1	29
5	Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 677-687.	2.5	28
6	Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. BMC Cancer, 2017, 17, 867.	2.6	28
7	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis, 2015, 95, 54-59.	1.9	27
8	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. Breast Cancer Research and Treatment, 2018, 168, 713-721.	2.5	20
9	Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients. Pharmaceutics, 2019, 11, 259.	4.5	19
10	Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes. Toxicological Research, 2016, 32, 207-213.	2.1	14
11	Development and validation of a sensitive LC–MS/MS method for the simultaneous quantitation of theophylline and its metabolites in rat plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 44-49.	2.3	13
12	Physicochemical Characterization and Toxicity of Decursin and Their Derivatives from <i>Angelica gigas</i> . Biological and Pharmaceutical Bulletin, 2012, 35, 1084-1090.	1.4	12
13	Population PK/PD analysis of metformin using the signal transduction model. British Journal of Clinical Pharmacology, 2012, 74, 815-823.	2.4	12
14	Quantitative determination of duloxetine and its metabolite in rat plasma by HPLCâ€MS/MS. Biomedical Chromatography, 2013, 27, 953-955.	1.7	12
15	Biopharmaceutical characterization of decursin and their derivatives for drug discovery. Drug Development and Industrial Pharmacy, 2013, 39, 1523-1530.	2.0	11
16	Effect of decursin on the pharmacokinetics of theophylline and its metabolites in rats. Journal of Ethnopharmacology, 2012, 144, 248-254.	4.1	10
17	A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Development and Industrial Pharmacy, 2014, 40, 1325-1329.	2.0	10
18	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Cancer Chemotherapy and Pharmacology, 2016, 78, 623-632.	2.3	9

JUNG-WOO CHAE

#	Article	IF	CITATIONS
19	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. Health and Quality of Life Outcomes, 2018, 16, 20.	2.4	9
20	A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption. BMC Pharmacology & amp; Toxicology, 2018, 19, 4.	2.4	9
21	Molecular design of anticancer drugs from marine fungi derivatives. RSC Advances, 2021, 11, 20173-20179.	3.6	9
22	Simultaneous determination of L-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in the plasma of rodents with LC-MS/MS. Arzneimittelforschung, 2011, 61, 340-346.	0.4	8
23	Prediction of Methionine and Homocysteine levels in Zucker diabetic fatty (ZDF) rats as a T2DM animal model after consumption of a Methionine-rich diet. Nutrition and Metabolism, 2018, 15, 14.	3.0	7
24	Quantitative Determination of Amitriptyline and Its Metabolite in Rat Plasma by Liquid Chromatography-tandem Mass Spectrometry. Bulletin of the Korean Chemical Society, 2012, 33, 2163-2167.	1.9	7
25	Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. Xenobiotica, 2014, 44, 975-987.	1.1	6
26	Effects of food intake on pharmacokinetics of mosapride in beagle dogs. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 497-499.	1.3	6
27	Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects. BMC Medical Research Methodology, 2017, 17, 154.	3.1	5
28	Chemotherapyâ€associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. Psycho-Oncology, 2018, 27, 1995-2001.	2.3	5
29	Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. Frontiers in Pharmacology, 2019, 10, 641.	3.5	5
30	LC-MS/MS Assay Validation for a New Immune Modulator, JHL45, and its Major Metabolite in Plasma: Application to Pharmacokinetic Studies in Rats. Bulletin of the Korean Chemical Society, 2009, 30, 2631-2636.	1.9	5
31	Effect of decursinol angelate on the pharmacokinetics of theophylline and its metabolites in rats. Food and Chemical Toxicology, 2012, 50, 3666-3672.	3.6	4
32	Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. Mitochondrion, 2020, 54, 65-71.	3.4	4
33	Development of a Pharmacokinetic Model Describing Neonatal Fc Receptorâ€Mediated Recycling of HL2351, a Novel Hybrid Fcâ€Fused Interleukinâ€1 Receptor Antagonist, to Optimize Dosage Regimen. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 584-595.	2.5	4
34	Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics, 2020, 12, 1040.	4.5	4
35	Dose Optimization of Vancomycin Using a Mechanism-based Exposure–Response Model in Pediatric Infectious Disease Patients. Clinical Therapeutics, 2021, 43, 185-194.e16.	2.5	4
36	External evaluation of the predictive performance of seven population pharmacokinetic models for phenobarbital in neonates. British Journal of Clinical Pharmacology, 2021, 87, 3878-3889.	2.4	4

JUNG-WOO CHAE

#	Article	IF	CITATIONS
37	Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 676-683.	0.6	4
38	Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Iranian Journal of Pharmaceutical Research, 2014, 13, 365-71.	0.5	4
39	Model-Based Equivalent Dose Optimization to Develop New Donepezil Patch Formulation. Pharmaceutics, 2022, 14, 244.	4.5	4
40	A novel HPLC–MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2015, 114, 121-126.	2.8	3
41	Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. Supportive Care in Cancer, 2018, 26, 3669-3670.	2.2	3
42	Clinical Evaluation of Acetaminophen–Galgeuntang Interaction Based on Population Approaches. Pharmaceutics, 2020, 12, 1182.	4.5	3
43	Effect of dissolved oxygen in alcoholic beverages and drinking water on alcohol elimination in humans. Alcohol, 2013, 47, 27-30.	1.7	2
44	Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans. International Journal of Molecular Sciences, 2020, 21, 1862.	4.1	2
45	Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections. Risk Management and Healthcare Policy, 2020, Volume 13, 685-695.	2.5	2
46	Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study Journal of Clinical Oncology, 2017, 35, 10018-10018.	1.6	2
47	The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. Pharmaceutics, 2022, 14, 1446.	4.5	2
48	Determination of influence of food intake after a single oral dose of mosapride in beagle dogs using nonlinear mixed effect modeling. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 590-595.	1.3	1
49	Determination of Matrine in Rat Plasma after Oral Administration of Novel Korean Herbal Medicine KIOM-MA128 and Application of PK. Journal of Analytical Methods in Chemistry, 2015, 2015, 1-6.	1.6	1
50	Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data. Pharmaceuticals, 2021, 14, 114.	3.8	1
51	Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers. Biopharmaceutics and Drug Disposition, 2021, 42, 94-102.	1.9	1
52	Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index. Risk Management and Healthcare Policy, 2021, Volume 14, 1855-1867.	2.5	1
53	Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models. Pharmaceuticals, 2021, 14, 654.	3.8	1
54	A web-based tool to predict chemotherapy-associated cognitive impairment during survivorship Journal of Clinical Oncology, 2017, 35, e21609-e21609.	1.6	1

JUNG-WOO CHAE

#	Article	IF	CITATIONS
55	Development and Validation of a Robust LC-MS/MS Method for the Simultaneous Quantification of Doxifluridine and its Two Metabolites in Beagle Dog Plasma. Bulletin of the Korean Chemical Society, 2010, 31, 2235-2241.	1.9	1
56	Development of a LC–MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 123-127.	2.3	0
57	Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients. Pharmaceutics, 2020, 12, 336.	4.5	Ο
58	Compatibility Study between Physiologically Based Pharmacokinetic (PBPK) and Compartmental PK Model Using Lumping Method: Application to the Voriconazole Case. Korean Journal of Clinical Pharmacy, 2021, 31, 125-135.	0.3	0
59	Analysis of Pembrolizumab-induced Blood Glucose Level Change in Cancer Patients. Korean Journal of Clinical Pharmacy, 2021, 31, 237-246.	0.3	Ο
60	Simultaneous Determination of Olanzapine and its Major Metabolite N-Desmethyl Olanzapine in Rat Plasma by HPLC-MS/MS: Application of PK in Rat. Bulletin of the Korean Chemical Society, 2013, 34, 2567-2568.	1.9	0
61	Population Pharmacokinetic Modeling and Simulation of Afloqualone to Predict Steady-state Exposure Levels. International Journal of Pharmacology, 2018, 14, 276-284.	0.3	0
62	A simple time-to-event model with NONMEM featuring right-censoring. Translational and Clinical Pharmacology, 2022, 30, 75.	0.9	0